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worldwide alignment, only 429 were included in subse-
quent analyses.)
Elson et al. criticize our inclusion of m.13105, which
they describe as “most often associated with African lin-
eages.”2 Although it is true that m.13105 is more common
in African samples, it is present at a frequency of 1.2% in
the 6,000 European samples we studied and at 3% in Hap-
Map CEU samples.3 We are perplexed as to why Elson et
al. write that this variant “should not have been used in
the analysis,”2 because it is in fact present in our samples
and could, in principle, influence traits. We do agree that
our catalogue is only as representative as the public data-
base used to create it. We note that association testing
performed using tags from 928 complete sequences is dra-
matically more complete than current standards.
Second, Elson et al. assert that our tag SNP and testing
strategy captures only a small fraction of European mtDNA
phylogeny.2,4 As shown in table 4 of our article,1 the com-
mon variants identified, as well as nine canonical Euro-
pean haplogroups, are well predicted by the tag SNPs and
specified haplotype tests. Perhaps Elson et al. do not con-
sider the specified haplotype tests that we performed, as,
in their example (shown in red in their fig. 1), although
no single SNP captures m.5046 of haplogroup W, a spec-
ified haplotype test (that we did perform) does. We do not
understand why Elson et al. argue that our strategy might
lead to “spurious associations,”2 nor do Elson et al. provide
an explanation of this claim.
Third, we agree that interaction among variants may
alter risk, which is why we performed pairwise tests involv-
ing all SNPs with nominal in the initial screen.1(p57)P ! .1
Marchini et al. showed this approach to be well powered.5,6
Finally, Elson et al. argue that limiting association tests
to the classical phylogeny and variants with “direct func-
tional consequences” will “increase the power of the
study.”2 We agree—under the model in which their assump-
tions are correct. Of course, under the model in which some
causal variants are not restricted to a classical haplogroup
or might not yet be suspected as contributing to disease,
power will decrease under the advocated approach.
RICHA SAXENA, PAUL I. W. DE BAKKER, LEIF C. GROOP,
MARK J. DALY, AND DAVID ALTSHULER
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Genetic Association Analysis of RHOB and
TXNDC3 in Osteoarthritis
To the Editor:
In the May 2006 issue of The American Journal of Human
Genetics, Mahr et al.1 reported an association with osteo-
arthritis (OA [MIM 165720]) for a SNP (rs49846015) lo-
cated immediately 5′ of the coding region of RHOB (on
chromosome 2p24.1 [MIM 165370]) and for a SNP
(rs4720262) located immediately 5′ of the coding region
of TXNDC3 (on chromosome 7p14.1 [MIM 607421]).
RHOB codes for a GTP-binding protein whereas TXNDC3
codes for a thioredoxin protein. The association study by
Mahr et al. was performed with 171 patients with OA (74%
females) who had undergone joint-replacement surgery
(68% knee and 32% hip) and with 182 healthy control
subjects (66% females), all of European white ethnicity.
Possession of a copy of the G allele of rs49846015 was an
OA risk factor ( ), as was possession of the T allelePp .0007
of rs4720262 ( ).Pp .0007
To assess the robustness of these associations, we have
genotyped the SNPs in our collection of 11,500 case pa-
tients with OA (mean age 65 years; age range 56–85 years)
and 1700 age-matched control subjects (mean age 69
years; age range 55–89 years). As in the study by Mahr et
al.,1 our case patients were ascertained by joint-replace-
ment surgery (hip, knee, or hip and knee) due to severe
end-stage OA. Our control subjects had no signs or symp-
toms of arthritis or joint disease (pain, swelling, tender-
ness, or restriction of movement). All case patients and
control subjects were individuals from the United King-
dom who are of white European ethnicity. Further details
about the ascertainment of our case patients and control
subjects have been published elsewhere.2 Ethical approval
for our study was obtained from the appropriate ethics
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Table 1. Association of RHOB SNP rs585017 between Our Case Patients with OA and Control Subjects
Group
Genotype
P for
Genotype
Allele
P for
Allele
OR for T Allele
(95% CI)AA AG GG A G
All case patientsa ( ):np 1,501 .32 1.0 1.00 (.87–1.16)
Count 800 577 124 2,177 825
Frequency (%) 53.3 38.4 8.3 72.5 27.5
All controls ( ):np 702 … … …
Count 365 289 48 1,019 385
Frequency (%) 52.0 41.2 6.8 72.6 27.4
Female case patients ( ):np 856 .28 .84 1.03 (.84–1.25)
Count 448 338 70 1,234 478
Frequency (%) 52.3 39.5 8.2 72.1 27.9
Female controls ( ):np 356 … … …
Count 182 153 21 517 195
Frequency (%) 51.1 43.0 5.9 72.6 27.4
Male case patients ( ):np 645 .78 .84 .97 (.79–1.20)
Count 352 239 54 943 347
Frequency (%) 54.6 37.1 8.4 73.1 26.9
Male controls ( ):np 346 … … …
Count 183 136 27 502 190
Frequency (%) 52.9 39.3 7.8 72.5 27.5
All kneesa ( ):np 352 .08 .94 1.01 (.83–1.24)
Count 192 125 35 509 195
Frequency (%) 54.5 35.5 9.9 72.3 27.7
Female knees ( ):np 195 .07 .71 .94 (.71–1.24)
Count 111 66 18 288 102
Frequency (%) 56.9 33.8 9.2 73.8 26.2
Male knees ( ):np 157 .54 .53 1.11 (.83–1.49)
Count 81 59 17 221 93
Frequency (%) 51.6 37.6 10.8 70.4 29.6
All hipsa ( ):np 1,067 .60 .87 1.02 (.87–1.18)
Count 560 422 85 1,542 592
Frequency (%) 52.5 39.6 8.0 72.3 27.7
Female hips ( ):np 615 .43 .52 1.08 (.88–1.32)
Count 310 255 50 875 355
Frequency (%) 50.4 41.5 8.1 71.1 28.9
Male hips ( ):np 452 .78 .62 .94 (.75–1.17)
Count 250 167 35 667 237
Frequency (%) 55.3 36.9 7.7 73.8 26.2
a In this analysis, 82 case patients who had undergone both hip replacement and knee replacement surgery were not included and were studied
as a separate stratum in the stratification analysis because of the small sample size.
committees, and informed consent was obtained from
each individual studied.
When planning our investigation, we noted that
rs49846015 was absent from dbSNP. A correspondence
with Sandra Mahr (personal communication) revealed
that rs585017 was the correct accession number for this
SNP. rs585017 and rs4720262 were genotyped by mass
spectrometry (homogeneous MassARRAY system [Se-
quenom]), and the genotype and allele distributions in
case and control groups were compared using standard x2
analysis-of-contingency tables. Tables 1 and 2 list the re-
sults for rs585017 and rs4720262, respectively. Both SNPs
were in Hardy-Weinberg equilibrium in the case and con-
trol groups. There were no significant differences (all P
values 1.05) in genotype or allele frequencies for either
SNP between the case and control groups. This was also
the case when the data were stratified by sex, with male
case patients compared with male control subjects and
female case patients compared with female control
subjects.
The frequency of the G allele of rs585017 in our study
is comparable to that in the study by Mahr et al.,1 with a
frequency of 27.4% in our control group and 23.9% in
Mahr et al.’s control group ( ). However, the fre-Pp .20
quency of the T allele of rs4720262 shows a highly sig-
nificant difference between the two studies, with a fre-
quency of 28.8% in our control group and 13.4% in Mahr
et al.’s control group ( ). In dbSNP, the T allele ofP ! .0005
rs4720262 is listed as having a frequency of 31.2% in the
AFD-EUR panel (23 unrelated American individuals of Eu-
ropean descent and one sample from a human variation
panel of 50 whites) and a frequency of 21.7% in a
HapMap-CEU panel (30 mother-father-child trios from
the CEPH collection of Utah residents with northern and
western European ancestry). Our T-allele frequency of
28.8% is between these two dbSNP-reported frequencies,
whereas the T-allele frequency of 13.4% reported by Mahr
et al. is substantially lower than both database frequencies.
This implies that the control frequencies reported for this
www.ajhg.org The American Journal of Human Genetics Volume 80 February 2007 385
Table 2. Association of TXNDC3 SNP rs4720262 between Our Case Patients with OA and Control Subjects
Group
Genotype
P for
Genotype
Allele
P for
Allele
OR for T Allele
(95% CI)CC CT TT C T
All case patientsa ( ):np 1,515 .92 .76 1.03 (.89–1.18)
Count 749 643 123 2,141 889
Frequency (%) 49.4 42.4 8.1 70.7 29.3
All control subjects ( ):np 706 … … …
Count 353 299 54 1,005 407
Frequency (%) 50.0 42.4 7.6 71.2 28.8
Female case patients ( ):np 868 .35 .17 1.15 (.95–1.39)
Count 406 384 78 1,196 540
Frequency (%) 46.8 44.2 9.0 68.9 31.1
Female control subjects ( ):np 360 … … …
Count 183 151 26 517 203
Frequency (%) 50.8 41.9 7.2 71.8 28.2
Male case patients ( ):np 647 .48 .26 .88 (.72–1.08)
Count 343 259 45 945 349
Frequency (%) 53.0 40.0 7.0 73.0 27.0
Male control subjects ( ):np 346 … … …
Count 170 148 28 488 204
Frequency (%) 49.1 42.8 8.1 70.5 29.5
All kneesa ( ):np 354 .82 .68 1.05 (.86–1.28)
Count 170 157 27 497 211
Frequency (%) 48.0 44.4 7.6 70.2 29.8
Female knees ( ):np 196 .21 .098 1.26 (.97–1.65)
Count 86 90 20 262 130
Frequency (%) 43.9 45.9 10.2 66.8 33.2
Male knees ( ):np 158 .29 .24 .82 (.61–1.11)
Count 84 67 7 235 81
Frequency (%) 53.2 42.4 4.4 74.4 25.6
All hipsa ( ):np 1,080 .89 .90 1.01 (.87–1.17)
Count 541 450 89 1,532 628
Frequency (%) 50.1 41.7 8.2 70.9 29.1
Female hips ( ):np 626 .54 .30 1.12 (.91–1.37)
Count 297 276 53 870 382
Frequency (%) 47.4 44.1 8.5 69.5 30.5
Male hips ( ):np 454 .41 .32 .89 (.71–1.11)
Count 244 174 36 662 246
Frequency (%) 53.7 38.3 7.9 72.9 27.1
a In this analysis, 81 case patients who had undergone both hip replacement and knee replacement surgery were not included and were studied
as a separate stratum in the stratification analysis because of the small sample size.
SNP by Mahr et al. may not accurately reflect the true
frequency of this SNP in Europeans of white ancestry.
To assess the power of our study, we conducted power
calculations by using Quanto, version 1.5,3,4 with the fol-
lowing options: an unmatched case-control study design,
a population risk of severe OA of 5%, a significance level
of 0.05, a G-allele frequency of 23.9% for rs585017, a T-
allele frequency of 13.4% for rs4720262, and a log-additive
inheritance mode. The allele frequencies and the inheri-
tance mode were selected to agree with the results of Mahr
et al. Table 3 lists, for each comparison, the minimum
odds ratio (OR) detectable with 80% power for our study.
We calculated an OR of 2.05 for the association with
rs585017 and an OR of 2.26 for the association with
rs4720262 from the results reported by Mahr et al. All the
ORs given in table 3 are lower than these values, indicating
that the sample sizes used in our study are more than
adequate to detect the ORs previously observed by Mahr
et al. In fact, the power to detect an OR of 2.05 for the
association with rs585017 was 99.7% for all compari-
sons, and the power to detect an OR of 2.26 for the as-
sociation with rs4720262 was99.6% for all comparisons.
Overall, our study does not replicate the previous find-
ings of an association between OA and the RHOB SNP
rs585017 and the TXNDC3 SNP rs4720262. Our study was
adequately powered to detect an association comparable
to that reported by Mahr et al., and we avoided potential
confounding factors by using the same disease ascertain-
ment (joint replacement of the hip or knee) and the same
ethnic group (Europeans of white ethnicity) used in the
original study. As more studies are reported, an accurate
estimation of the effect of these two SNPs on OA suscep-
tibility will become apparent.
JOHN LOUGHLIN, INGRID MEULENBELT, JOSINE MIN,
ZEHRA MUSTAFA, JANET S. SINSHEIMER,
ANDREW CARR, AND P. ELINE SLAGBOOM
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
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Table 3. The Minimum Detectable ORs for Our Analysis under the Log-Additive
Model with Power 80% and a Significance Level of 5%
Comparison
Minimum Detectable OR
RHOB SNP
rs585017
TXNDC3 SNP
rs4720262
All case patients vs. all control subjects 1.23 1.30
Female case patients vs. female control subjects 1.34 1.42
Male case patients vs. male control subjects 1.36 1.45
All knees vs. all control subjects 1.35 1.43
Female knees vs. female control subjects 1.49 1.62
Male knees vs. male control subjects 1.54 1.68
All hips vs. all control subjects 1.25 1.31
Female hips vs. female control subjects 1.36 1.47
Male hips vs. male control subjects 1.38 1.49
dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/ (for
rs585017 and rs4720262)
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for osteoarthritis, RHOB, and TXNDC3)
Quanto, http://hydra.usc.edu/gxe (for power calculations)
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Reply to Loughlin et al.
To the Editor:
We very much appreciate the effort Loughlin and col-
leagues1 took in trying to replicate our finding of an as-
sociation between osteoarthritis (MIM 165720) and the
RHOB (MIM 165370) SNP rs585017 and the TXNDC3
(MIM 607421) SNP rs4720262.
In our study,2 odds ratios (ORs) of 2.1 and 2.3 describe
the association between osteoarthritis and the RHOB and
TXNDC3 SNPs, respectively, and we had 80% power to
detect ORs as small as 1.6 and 1.8, respectively. Both SNPs
were in Hardy-Weinberg equilibrium in the control group,
so we can confidently rule out obvious methodological
flaws.
Loughlin et al.1 used the same disease ascertainment
that we did (joint replacement of the hip and/or knee),
and they too analyzed Europeans of white ethnicity. Why
then did the study fail? And, by extension, why did all
the previous genomewide scans—no matter how com-
parable the strategies to elucidate the genetics of osteo-
arthritis3,4—not culminate in a coherent set of results?
Obviously, one can always call for an even higher sta-
tistical power or claim that reported associations are spu-
rious. But let us refocus on the disease at hand; osteoar-
thritis is a complex disease, and if there was a simple
genetic pattern involved, surely we would have identified
it by now.5 Assuming that the osteoarthritis pathogenesis
requires a delicate interplay between individual genetic
polymorphisms and regional environmental changes, we
need to question the comparability of a British study and
an eastern German study for disease-associated genes. Ad-
ditionally, we need to identify the strata that reflect the
different etiologies. In fact, table 3 in the letter by Lough-
lin et al.1 might also suggest that increased ORs cannot be
excluded for the strata “osteoarthritis of the knee.” Our
own data support a recessive model for RHOB and a dom-
inant model for TXNDC3. The combination of both risk
factors yields an OR 19; however, our sample numbers are
small. To facilitate testing our hypothesis in the U.K. co-
hort, we emphasize the suggestion that all tested data be
reported as online supplements in their original forms.5
Loughlin et al.1 also raise the issue of the different fre-
quencies for the TXNDC3 SNP rs4720262 in the control
subjects—13.4% in our cohort and 28.8% in the U.K. co-
hort. Indeed, the Ensembl Genome Browser reports a high
variability for this particular SNP, with 2.2% in African
Americans as the lowest. Among Americans of European
descent, the frequencies vary from 21.7% (in HapMap,
among 60 individuals) to 31.2% (in PERLEGEN, among
25 individuals). This points to an elevated variability in
